Answers are grounded in this paper and cite their sources.
Reviews cardioprotective mechanisms of HDL cholesterol and clinical evidence, indicating HDL-C should guide overall cardiovascular risk management.
A low level of high-density lipoprotein cholesterol (HDL-C) is an important risk factor for cardiovascular disease. Epidemiological and clinical studies provide evidence that HDL-C levels are linked to rates of coronary events. The cardioprotective effects of HDL-C have been attributed to its role in reverse cholesterol transport, its effects on endothelial cells, and its antioxidant activity. Although some clinical trials suggest a benefit of raising HDL-C to reduce risk, further studies are needed, and HDL-C is still not considered a primary target of therapy in the National Cholesterol Education Program guidelines. However, HDL-C should be considered as part of the patient's overall profile of established risk factors in determining treatment strategies.
No takes yet. Share an insight, caveat, or question.
Assmann et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: